Greenwich LifeSciences (Greenwich LifeSciences) Total Stockholders Equity : $5.12 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Greenwich LifeSciences Total Stockholders Equity?

Greenwich LifeSciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $5.12 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Greenwich LifeSciences's Book Value per Share for the quarter that ended in Mar. 2024 was $0.40. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Greenwich LifeSciences's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.00.

Greenwich LifeSciences Total Stockholders Equity Historical Data

The historical data trend for Greenwich LifeSciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greenwich LifeSciences Total Stockholders Equity Chart

Greenwich LifeSciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

-1.35

27.63

26.83

13.21

6.70

Greenwich LifeSciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															11.68	10.65	8.85	6.70	5.12

Greenwich LifeSciences (NAS:GLSI) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Greenwich LifeSciences's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(5.121	-	0)	/	12.8753
	=	0.40

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Greenwich LifeSciences's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	5.121
	=	0.00

Greenwich LifeSciences Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Greenwich LifeSciences's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Greenwich LifeSciences (Greenwich LifeSciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenwich LifeSciences Inc (NAS:GLSI) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477

Website

https://www.greenwichlifesciences.com

Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells in order to inhibit the spread of cancer.

Executives

Snehal Patel	director, officer: CHIEF EXECUTIVE OFFICER	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Jaye Thompson	officer: VPC AND REGULATORY AFFAIRS	2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Frank Joseph Daugherty	director, officer: CHIEF MEDICAL OFFICER	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kenneth Hallock	director	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
David Mcwilliams	director	2575 WEST BELLFORT STREET, HOUSTON TX 77054-9816
Eric Rothe	director	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kinnary Patel	10 percent owner	3992 BLUEBONNET DR., BUILDING 14, STAFFORD TX 77477
Panjaj Amrit Patel	10 percent owner	50726 LAKESIDE DRIVE, GRANGER IN 46530